These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Author: Sobel JD, Schmitt C, Meriwether C. Journal: Obstet Gynecol; 1989 Mar; 73(3 Pt 1):330-4. PubMed ID: 2644595. Abstract: The management of women with recurrent and chronic vulvovaginal candidiasis continues to present a therapeutic challenge. In a prospective double-blind randomized study of 42 women with recurrent candidal vaginitis, clotrimazole 500-mg vaginal suppositories, administered once weekly for 2 weeks, induced clinical remission in 38 patients (90.4%) and achieved mycologic negative status in 83% of subjects. Thereafter, asymptomatic patients were randomized to receive monthly prophylactic vaginal tablets of clotrimazole 500 mg or placebo once a month. During the prophylactic phase, patients receiving placebo developed recurrences of symptomatic candida vaginitis at an extremely high rate, such that only one-third remained asymptomatic at the end of 6 months. In comparison, patients receiving clotrimazole demonstrated moderate protection from recurrence; which was maximal and statistically significant during the first 3 months of prophylaxis only (P less than .05). During the prophylactic period overall, attack rates were reduced by one-third with clotrimazole. No adverse reactions were observed with the administration of clotrimazole. In summary, clotrimazole therapy was successful in inducing an initial therapeutic response, but achieved only a modest long-term protective effect. Additional clinical benefit may be possible with more frequent clotrimazole prophylactic administration.[Abstract] [Full Text] [Related] [New Search]